All Updates

All Updates

icon
Filter
FDA approval
Theranica's Nerivio receives expanded FDA approval for migraine treatment in children
Preventive Healthcare
Nov 14, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Nov 14, 2024

Theranica's Nerivio receives expanded FDA approval for migraine treatment in children

FDA approval

  • The FDA has expanded the age indication for Theranica's Nerivio remote electrical neuromodulation device for migraine treatment in patients aged eight and above. Previously, the device was only approved for patients 12 years and older. This makes it the first FDA-cleared non-drug therapy for acute treatment and the only prescribed preventive treatment of migraine for children in this age group.

  • The expanded approval was supported by real-world study data of children aged 6–11 years. The study showed that 72.2% of patients reported consistent headache relief and 83.3% reported consistent functional disability relief two hours post-treatment. No adverse events were reported in the study.

  • Analyst QuickTake: Nerivio received FDA approval for treating acute migraines in May 2019, and, in January 2021 , the firm obtained FDA clearance to market its product as a treatment for episodic or chronic migraines while expanding treatment to adolescents. Its closest competitor, gammaCore from electroCore , is the only other device approved for adolescents.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.